# ICON plc (ICLR) — Stock CV

ICON plc is a $12.7B healthcare company. Revenue grew 0.8% over the last year, it keeps 3¢ of every dollar of sales as profit, and its net debt equals ~2.5 years of free cash flow. It trades at 182.1× earnings.

> Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies.

## Identity

- **Ticker**: ICLR
- **Sector**: Healthcare
- **Industry**: Diagnostics & Research
- **Employees**: 40 100
- **Website**: https://www.iconplc.com
- **Market cap**: $12.7B
- **Last price**: $164.17
- **Financial profile**: Mixed

## Vitals (FY2025)

- **Revenue**: $8.25B
- **Net income**: $214M
- **Free cash flow**: $1.03B
- **Net debt**: $2.60B
- **P/E**: 182.1
- **Revenue growth (YoY)**: 0.8%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 67 |
| Growth | 63 |
| Profitability | 21 |
| Health | 38 |
| Quality | 90 |
| Moat | 43 |

## Qualifications (beginner checklist) — 7 of 10 passed

- [x] Revenue growing — +0.8% YoY
- [x] Profitable — $214M FY2025
- [ ] Profit growing — -22.0% YoY
- [x] Generates cash — $1.03B FY2025
- [x] Debt under control — ~2.5y of cash flow to repay
- [x] Established company — $12.7B market cap
- [ ] Not printing shares — +16.0% shares over ~5y
- [x] Proven track record — 5/5 profitable years
- [x] Financially stable — Altman Z 1.9 — grey
- [ ] Valuation not extreme — P/E 182.1

## Experience (career milestones)

- **FY2024** — Best year on record: $727M net income
- **FY2021** — Profitable every year on record: 5 consecutive profitable years in our data
- **FY2021** — Revenue already above $1B: $5.48B in first reported year
- **FY2021** — Positive free cash flow every year since: 5-year streak

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $5.48B | $153M | $421M |
| FY2022 | $7.74B | $505M | $1.02B |
| FY2023 | $8.05B | $554M | $1.28B |
| FY2024 | $8.19B | $727M | $1.01B |
| FY2025 | $8.25B | $214M | $1.03B |

---

Source: https://stockcv.com/ICLR — derived from company filings; may be delayed or incomplete. Information, not investment advice.